Top

Published in:

01-09-2020 | Multiple Myeloma | Original Article

Depressive symptoms, mental health-related quality of life, and survival among older patients with multiple myeloma

Authors: Ali Alobaidi, Nadia A. Nabulsi, Brian Talon, Alemseged A. Asfaw, Jifang Zhou, Lisa K. Sharp, Karen Sweiss, Pritesh R. Patel, Naomi Y. Ko, Brian C.-H. Chiu, Gregory S. Calip

Published in: Supportive Care in Cancer | Issue 9/2020

Abstract

Purpose

To examine the impact of pre-diagnosis depressive symptoms and mental health-related quality of life (HRQOL) on survival among older patients with multiple myeloma (MM).

Methods

We performed a retrospective cohort study using the Surveillance, Epidemiology, and End Results-Medicare Health Outcomes Survey data resource. Patients aged 65 years and older diagnosed with first primary MM between 1998 and 2014 were identified, and presence of depressive symptoms was determined based on responses to 3 depression screening questions prior to MM diagnosis. Veterans RAND 12 mental component summary (MCS) scores were analyzed to evaluate mental HRQOL. We used multivariable Cox proportional hazards models to estimate hazard ratios (HR) and 95% confidence intervals (CI) for risks of all-cause and cancer-specific mortality.

Results

Of 522 patients, mean (SD) age at diagnosis was 76.9 (6.1) years and 158 (30%) reported depressive symptoms. Patients with depressive symptoms had a higher number of comorbid conditions and nearly all (84%) scored below the median MCS. Pre-diagnosis depressive symptoms were not associated with all-cause (HR = 1.01, 95% CI 0.79–1.29) or cancer-specific mortality (HR = 0.94, 95% CI 0.69–1.28). MM patients scoring in the second MCS tertile (vs the highest tertile) had a modestly increased risk of all-cause (HR = 1.19, 95% CI 0.91–1.55) and cancer-specific mortality (HR = 1.17, 95% CI 0.86–1.60), but these estimates were not statistically significant.

Conclusion

Pre-diagnosis depressive symptoms and lower mental HRQoL did not impact survival among older MM patients. Highly prevalent depressive symptoms among older MM patients deserve clinical attention. Such efforts can inform clinicians in tailoring care for this vulnerable population.

Available only for authorised users

Palumbo A, Anderson K (2011) Multiple myeloma. N Engl J Med 364(11):1046–1060. https://doi.org/10.1056/NEJMra1011442 CrossRefPubMed

Kyle RA, Gertz MA, Witzig TE, Lust JA, Lacy MQ, Dispenzieri A, Fonseca R, Rajkumar SV, Offord JR, Larson DR, Plevak ME, Therneau TM, Greipp PR (2003) Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 78(1):21–33. https://doi.org/10.4065/78.1.21 CrossRefPubMed

Cancer Stat Facts: Myeloma. National Cancer Institute. Bethesda, MD. https://seer.cancer.gov/statfacts/html/mulmy.html. Accessed March 28th, 2019

Bell JR (1997) Underdiagnosis of depression in primary care: by accident or design? JAMA 277(18):1433CrossRefPubMed

Serby M, Yu M (2003) Overview: depression in the elderly. Mt Sinai J Med 70(1):38–44PubMed

Djernes JK (2006) Prevalence and predictors of depression in populations of elderly: a review. Acta Psychiatr Scand 113(5):372–387. https://doi.org/10.1111/j.1600-0447.2006.00770.x CrossRefPubMed

Lutgendorf SK, Andersen BL (2015) Biobehavioral approaches to cancer progression and survival: mechanisms and interventions. Am Psychol 70(2):186–197. https://doi.org/10.1037/a0035730 CrossRefPubMedPubMedCentral

Bortolato B, Hyphantis TN, Valpione S, Perini G, Maes M, Morris G, Kubera M, Köhler CA, Fernandes BS, Stubbs B, Pavlidis N, Carvalho AF (2017) Depression in cancer: the many biobehavioral pathways driving tumor progression. Cancer Treat Rev 52:58–70. https://doi.org/10.1016/j.ctrv.2016.11.004 CrossRefPubMed

Buscariollo DL, Cronin AM, Borstelmann NA, Punglia RS (2019) Impact of pre-diagnosis depressive symptoms and health-related quality of life on treatment choice for ductal carcinoma in situ and stage I breast cancer in older women. Breast Cancer Res Treat 173(3):709–717. https://doi.org/10.1007/s10549-018-5006-5 CrossRefPubMed

10.

El-Jawahri A, Chen YB, Brazauskas R, He N, Lee SJ, Knight JM et al (2017) Impact of pre-transplant depression on outcomes of allogeneic and autologous hematopoietic stem cell transplantation. Cancer 123(10):1828–1838. https://doi.org/10.1002/cncr.30546 CrossRefPubMed

11.

Fann JR, Thomas-Rich AM, Katon WJ, Cowley D, Pepping M, McGregor BA, Gralow J (2008) Major depression after breast cancer: a review of epidemiology and treatment. Gen Hosp Psychiatry 30(2):112–126. https://doi.org/10.1016/j.genhosppsych.2007.10.008 CrossRefPubMed

12.

Calip GS, Xing S, Jun DH, Lee WJ, Hoskins KF, Ko NY (2017) Polypharmacy and adherence to adjuvant endocrine therapy for breast cancer. J Oncol Pract 13(5):e451–ee62. https://doi.org/10.1200/JOP.2016.018317 CrossRefPubMed

13.

Liang X, Margolis KL, Hendryx M, Reeves K, Wassertheil-Smoller S, Weitlauf J, Danhauer SC, Chlebowski RT, Caan B, Qi L, Lane D, Lavasani S, Luo J (2017) Effect of depression before breast cancer diagnosis on mortality among postmenopausal women. Cancer 123(16):3107–3115. https://doi.org/10.1002/cncr.30688 CrossRefPubMed

14.

Mols F, Husson O, Roukema JA, van de Poll-Franse LV (2013) Depressive symptoms are a risk factor for all-cause mortality: results from a prospective population-based study among 3,080 cancer survivors from the PROFILES registry. J Cancer Surviv 7(3):484–492. https://doi.org/10.1007/s11764-013-0286-6 CrossRefPubMed

15.

Pinquart M, Duberstein PR (2010) Depression and cancer mortality: a meta-analysis. Psychol Med 40(11):1797–1810. https://doi.org/10.1017/S0033291709992285 CrossRefPubMedPubMedCentral

16.

Satin JR, Linden W, Phillips MJ (2009) Depression as a predictor of disease progression and mortality in cancer patients: a meta-analysis. Cancer 115(22):5349–5361. https://doi.org/10.1002/cncr.24561 CrossRefPubMed

17.

Lutgendorf SK, De Geest K, Bender D, Ahmed A, Goodheart MJ, Dahmoush L et al (2012) Social influences on clinical outcomes of patients with ovarian cancer. J Clin Oncol 30(23):2885–2890. https://doi.org/10.1200/JCO.2011.39.4411 CrossRefPubMedPubMedCentral

18.

Doll KM, Pinheiro LC, Reeve BB (2017) Pre-diagnosis health-related quality of life, surgery, and survival in women with advanced epithelial ovarian cancer: a SEER-MHOS study. Gynecol Oncol 144(2):348–353. https://doi.org/10.1016/j.ygyno.2016.12.005 CrossRefPubMed

19.

Pinheiro LC, Reeve BB (2018) Investigating the prognostic ability of health-related quality of life on survival: a prospective cohort study of adults with lung cancer. Support Care Cancer 26(11):3925–3932. https://doi.org/10.1007/s00520-018-4265-3 CrossRefPubMed

20.

Pinheiro LC, Zagar TM, Reeve BB (2017) The prognostic value of pre-diagnosis health-related quality of life on survival: a prospective cohort study of older Americans with lung cancer. Qual Life Res 26(7):1703–1712. https://doi.org/10.1007/s11136-017-1515-7 CrossRefPubMedPubMedCentral

21.

Reeve BB, Potosky AL, Smith AW, Han PK, Hays RD, Davis WW, Arora NK, Haffer SC, Clauser SB (2009) Impact of cancer on health-related quality of life of older Americans. J Natl Cancer Inst 101(12):860–868. https://doi.org/10.1093/jnci/djp123 CrossRefPubMedPubMedCentral

22.

Ambs A, Warren JL, Bellizzi KM, Topor M, Haffer SC, Clauser SB (2008) Overview of the SEER--Medicare Health Outcomes Survey linked dataset. Health Care Financ Rev 29(4):5–21PubMedPubMedCentral

23.

Overview of the SEER Program. https://seer.cancer.gov/about/overview.html. Accessed March 28th, 2019

24.

Warren JL, Klabunde CN, Schrag D, Bach PB, Riley GF (2002) Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care 40(8 Suppl):IV-3–IV18. https://doi.org/10.1097/01.MLR.0000020942.47004.03 CrossRef

25.

SEER-MHOS Response Rates. 2018. https://healthcaredelivery.cancer.gov/seer-mhos/aboutdata/table.response.rates.html. Accessed March 28th, 2019

26.

Clark CJ, Fino NF, Liang JH, Hiller D, Bohl J (2016) Depressive symptoms in older long-term colorectal cancer survivors: a population-based analysis using the SEER-Medicare healthcare outcomes survey. Support Care Cancer 24(9):3907–3914. https://doi.org/10.1007/s00520-016-3227-x CrossRefPubMedPubMedCentral

27.

White AJ, Reeve BB, Chen RC, Stover AM, Irwin DE (2014) Coexistence of urinary incontinence and major depressive disorder with health-related quality of life in older Americans with and without cancer. J Cancer Surviv 8(3):497–507. https://doi.org/10.1007/s11764-014-0360-8 CrossRefPubMedPubMedCentral

28.

Rost K, Burnam MA, Smith GR (1993) Development of screeners for depressive disorders and substance disorder history. Med Care 31(3):189–200CrossRefPubMed

29.

Whooley MA, Avins AL, Miranda J, Browner WS (1997) Case-finding instruments for depression. Two questions are as good as many. J Gen Intern Med 12(7):439–445CrossRefPubMedPubMedCentral

30.

Selim AJ, Rogers W, Fleishman JA, Qian SX, Fincke BG, Rothendler JA, Kazis LE (2009) Updated U.S. population standard for the Veterans RAND 12-item Health Survey (VR-12). Qual Life Res 18(1):43–52. https://doi.org/10.1007/s11136-008-9418-2 CrossRefPubMed

31.

Fleishman JA, Selim AJ, Kazis LE (2010) Deriving SF-12v2 physical and mental health summary scores: a comparison of different scoring algorithms. Qual Life Res 19(2):231–241. https://doi.org/10.1007/s11136-009-9582-z CrossRefPubMed

32.

Varadhan R, Weiss CO, Segal JB, Wu AW, Scharfstein D, Boyd C (2010) Evaluating health outcomes in the presence of competing risks: a review of statistical methods and clinical applications. Med Care 48(6 Suppl):S96–105. doi:https://doi.org/10.1097/MLR.0b013e3181d99107

33.

Mian HS, Wildes TM, Fiala MA (2018) Development of a Medicare Health Outcomes Survey Deficit-Accumulation Frailty Index and its application to older patients with newly diagnosed multiplemyeloma. JCO Clin Cancer Inform 2:1–13. https://doi.org/10.1200/cci.18.00043 CrossRef

34.

Kent EE, Ambs A, Mitchell SA, Clauser SB, Smith AW, Hays RD (2015) Health-related quality of life in older adult survivors of selected cancers: data from the SEER-MHOS linkage. Cancer 121(5):758–765. https://doi.org/10.1002/cncr.29119 CrossRefPubMed

35.

Martino SC, Elliott MN, Haviland AM, Saliba D, Burkhart Q, Kanouse DE (2016) Comparing the health care experiences of Medicare beneficiaries with and without depressive symptoms in Medicare managed care versus fee-for-service. Health Serv Res 51(3):1002–1020. https://doi.org/10.1111/1475-6773.12359 CrossRefPubMed

36.

Pourat N, Kagawa-Singer M, Wallace SP (2006) Are managed care Medicare beneficiaries with chronic conditions satisfied with their care? J Aging Health 18(1):70–90. https://doi.org/10.1177/0898264305280997 CrossRefPubMed

37.

Seiler A, Jenewein J (2019) Resilience in cancer patients. Front Psychiatry 10:208. https://doi.org/10.3389/fpsyt.2019.00208 CrossRefPubMedPubMedCentral

38.

Dickens AP, Richards SH, Greaves CJ, Campbell JL (2011) Interventions targeting social isolation in older people: a systematic review. BMC Public Health 11:647. https://doi.org/10.1186/1471-2458-11-647 CrossRefPubMedPubMedCentral

39.

Duijts SF, van Egmond MP, Spelten E, van Muijen P, Anema JR, van der Beek AJ (2014) Physical and psychosocial problems in cancer survivors beyond return to work: a systematic review. Psychooncology 23(5):481–492. https://doi.org/10.1002/pon.3467 CrossRefPubMed

Title: Depressive symptoms, mental health-related quality of life, and survival among older patients with multiple myeloma
Authors: Ali Alobaidi
Nadia A. Nabulsi
Brian Talon
Alemseged A. Asfaw
Jifang Zhou
Lisa K. Sharp
Karen Sweiss
Pritesh R. Patel
Naomi Y. Ko
Brian C.-H. Chiu
Gregory S. Calip
Publication date: 01-09-2020
Publisher: Springer Berlin Heidelberg
Keywords: Multiple Myeloma
Mood Disorders
Affective Disorder
Published in: Supportive Care in Cancer / Issue 9/2020
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-019-05246-6

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 9/2020

Reporting of paclitaxel-induced peripheral neuropathy symptoms to clinicians among women with breast cancer: a qualitative study

Correction to: Preventing emergency department visits among patients with cancer: a scoping review

A Chinese version of the chemotherapy-induced alopecia distress scale based on reliability and validity assessment in breast cancer patients

The quality of care of the dying in hospital—next-of-kin perspectives

Progressive muscle relaxation is effective in preventing and alleviating of chemotherapy-induced nausea and vomiting among cancer patients: a systematic review of six randomized controlled trials

The perception of Israeli oncology staff members regarding advance care planning

Keynote webinar | Spotlight on antibody–drug conjugates in cancer